Key result
Autologous bone marrow MNC infusion is safe and linked to ~1-point lower 90-day mRS in acute stroke.
Answers are grounded in this paper and cite their sources.
Cellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single-arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS). Patients with moderate severity of AIS underwent bone marrow harvest followed by IV reinfusion of MNCs within 24-72 hours of onset. A target dose of 10 million cells per kilogram was chosen based on preclinical data. Patients were followed up daily during hospitalization and at 1, 3, 6, 12, and 24 months for incidence of adverse events using laboratory, clinical (12 months), and radiological (24 months) parameters. The trial was powered to detect severe adverse events (SAEs) with incidences of at least 10% and planned to enroll 30 patients. Primary outcomes were study-related SAEs and the proportion of patients successfully completing study intervention. A propensity score-based matched control group was used for the estimation of effect size (ES) for day-90 modified Rankin score (mRS). There were no study-related SAEs and, based on a futility analysis, enrolment was stopped after 25 patients. All patients successfully completed study intervention and most received the target dose. Secondary analysis estimated the ES to be a reduction of 1 point (95% confidence interval: 0.33-1.67) in median day-90 mRS for treated patients as compared with the matched control group. Bone marrow harvest and infusion of MNCs is safe and feasible in patients with AIS. The estimated ES is helpful in designing future randomized controlled trials. Stem Cells 2019;37:1481-1491.
No takes yet. Share an insight, caveat, or question.
Vahidy et al. (2019) studied Acute ischemic stroke (n=25). Intravenous autologous bone marrow mononuclear cells (MNCs) vs. Propensity score-matched control group was evaluated on Study-related severe adverse events (SAEs) and the proportion of patients successfully completing study intervention (Median difference -1 point in day-90 mRS, 95% CI 0.33-1.67). IV autologous bone marrow MNC infusion in acute ischemic stroke had 0% study-related SAEs, 100% completion, and reduced median day-90 mRS by 1 point vs matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: